title: Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients.
abstract: Telmisartan, a new angiotensin II type 1 receptor blocker (ARB), was recently reported to stimulate PPARgamma, and stronger effects of Telmisartan on insulin sensitivity has been expected than the class effect of ARB. In the present study, we examined the effects of Telmisartan on insulin sensitivity and adipokine levels in hypertensive and type 2 diabetic patients. Outpatients with both hypertension and type 2 diabetes mellitus (n=36; male 23, female 13), received 20-40mg Telmisartan orally once daily for 6 months. Physical examinations and blood or urine tests were performed before and 3 or 6 months after starting Telmisartan treatment. Results were statistically compared using Wilcoxon analysis. Telmisartan treatment for 3 or 6 months reduced systolic and diastolic blood pressure and urinary albumin excretion. Fasting plasma glucose, HbA1c, total and HDL-cholesterol, triglyceride, body weight, BMI and waist length were not changed. Fasting IRI and HOMA-IR were significantly decreased after Telmisartan treatment, suggesting the improved insulin sensitivity. Total and high molecular adiponectin were not changed. Interestingly, serum leptin was significantly increased by 3 months Telmisartan treatment, suggesting a possible involvement of leptin in improved insulin sensitivity. In conclusion, Telmisartan improved insulin resistance with increased serum leptin level in hypertensive and type 2 diabetic patients.
authors.affiliation: The First Department of Internal Medicine, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan. isaousui-tym@umin.ac.jp
authors.forename: Isao
authors.initials: I
authors.lastname: Usui
authors.forename: Shiho
authors.initials: S
authors.lastname: Fujisaka
authors.forename: Katsuya
authors.initials: K
authors.lastname: Yamazaki
authors.forename: Atsuko
authors.initials: A
authors.lastname: Takano
authors.forename: Shiho
authors.initials: S
authors.lastname: Murakami
authors.forename: Yu
authors.initials: Y
authors.lastname: Yamazaki
authors.forename: Masaharu
authors.initials: M
authors.lastname: Urakaze
authors.forename: Haruo
authors.initials: H
authors.lastname: Hachiya
authors.forename: Michiyo
authors.initials: M
authors.lastname: Takata
authors.forename: Satoko
authors.initials: S
authors.lastname: Senda
authors.forename: Minoru
authors.initials: M
authors.lastname: Iwata
authors.forename: Akira
authors.initials: A
authors.lastname: Satoh
authors.forename: Toshiyasu
authors.initials: T
authors.lastname: Sasaoka
authors.forename: Norel Dim
authors.initials: ND
authors.lastname: Ak
authors.forename: Rie
authors.initials: R
authors.lastname: Temaru
authors.forename: Masashi
authors.initials: M
authors.lastname: Kobayashi
mesh_terms: D052242:Adiponectin / Q000097:blood; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000419:Albuminuria / Q000517:prevention & control; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D001565:Benzoates / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D015992:Body Mass Index; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000503:physiopathology*; D003925:Diabetic Angiopathies / Q000188:drug therapy*; D003927:Diet, Diabetic; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D020738:Leptin / Q000097:blood*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D000077333:Telmisartan
chemical_list: D052242:Adiponectin; D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001565:Benzoates; D007004:Hypoglycemic Agents; D020738:Leptin; D008055:Lipids; D000077333:Telmisartan